[go: up one dir, main page]

MX9701538A - Sales de un derivado del indol contra la migraña. - Google Patents

Sales de un derivado del indol contra la migraña.

Info

Publication number
MX9701538A
MX9701538A MX9701538A MX9701538A MX9701538A MX 9701538 A MX9701538 A MX 9701538A MX 9701538 A MX9701538 A MX 9701538A MX 9701538 A MX9701538 A MX 9701538A MX 9701538 A MX9701538 A MX 9701538A
Authority
MX
Mexico
Prior art keywords
salts
indole derivative
migraine
migraine indole
polymorphic form
Prior art date
Application number
MX9701538A
Other languages
English (en)
Inventor
Valerie Denise Harding
Ross James Macrae
Ronald James Ogilvie
Original Assignee
Pfizer Res And Dev Company
Sa Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10760474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9701538(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Res And Dev Company, Sa Nv filed Critical Pfizer Res And Dev Company
Publication of MX9701538A publication Critical patent/MX9701538A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Reciprocating, Oscillating Or Vibrating Motors (AREA)

Abstract

La invencion se refiere a una forma polimorfica alfa de un compuesto de formula (I): a procedimientos para su preparacion, a una forma polimorfica beta intermedia y a composiciones farmacéuticas y a sus usos terapéuticos.
MX9701538A 1994-08-27 1995-05-17 Sales de un derivado del indol contra la migraña. MX9701538A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9417310A GB9417310D0 (en) 1994-08-27 1994-08-27 Therapeutic agents
PCT/EP1995/001914 WO1996006842A1 (en) 1994-08-27 1995-05-17 Salts of an anti-migraine indole derivative

Publications (1)

Publication Number Publication Date
MX9701538A true MX9701538A (es) 1997-05-31

Family

ID=10760474

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701538A MX9701538A (es) 1994-08-27 1995-05-17 Sales de un derivado del indol contra la migraña.

Country Status (45)

Country Link
US (2) US6110940A (es)
EP (1) EP0776323B1 (es)
JP (1) JP2904588B2 (es)
KR (1) KR100228952B1 (es)
CN (1) CN1066727C (es)
AP (1) AP576A (es)
AT (1) ATE163182T1 (es)
AU (1) AU691005B2 (es)
BG (1) BG61840B1 (es)
BR (1) BRPI9503812B1 (es)
CA (1) CA2198599C (es)
CO (1) CO4410334A1 (es)
CZ (1) CZ287693B6 (es)
DE (1) DE69501620T2 (es)
DK (1) DK0776323T3 (es)
DZ (1) DZ1923A1 (es)
EG (1) EG23822A (es)
ES (1) ES2112650T3 (es)
FI (1) FI113768B (es)
GB (1) GB9417310D0 (es)
GR (1) GR3026475T3 (es)
HR (1) HRP950460B1 (es)
HU (1) HU227822B1 (es)
IL (1) IL115013A (es)
IS (1) IS1850B (es)
LV (1) LV11800B (es)
MA (1) MA23650A1 (es)
MX (1) MX9701538A (es)
MY (1) MY113733A (es)
NO (1) NO311297B1 (es)
NZ (1) NZ288210A (es)
OA (1) OA10600A (es)
PE (1) PE41596A1 (es)
PL (1) PL180867B1 (es)
RO (1) RO116400B1 (es)
RU (1) RU2159241C2 (es)
SA (1) SA95160156B1 (es)
SI (1) SI9520091B (es)
SK (1) SK282922B6 (es)
TN (1) TNSN95092A1 (es)
TR (1) TR199501061A2 (es)
UA (1) UA45980C2 (es)
WO (1) WO1996006842A1 (es)
YU (1) YU49287B (es)
ZA (1) ZA957142B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
GB9714081D0 (en) * 1997-07-03 1997-09-10 Pfizer Ltd Pharmaceutical compositions
AU724728B2 (en) * 1997-07-03 2000-09-28 Pfizer Inc. Pharmaceutical compositions containing eletriptan hemisulphate and caffeine
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
US7108970B2 (en) 2000-01-07 2006-09-19 Transform Pharmaceuticals, Inc. Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
US6977723B2 (en) 2000-01-07 2005-12-20 Transform Pharmaceuticals, Inc. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
GB0008563D0 (en) 2000-04-07 2000-05-24 Cambridge Discovery Chemistry Investigating different physical and/or chemical forms of materials
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
US20030166704A1 (en) * 2000-12-20 2003-09-04 Pfizer Inc. New process
GB0031094D0 (en) * 2000-12-20 2001-01-31 Pfizer Ltd New Process
US6579898B2 (en) 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
EP1615635A1 (en) 2003-04-11 2006-01-18 Pfizer Limited Pharmaceutical combination comprising eletriptan and sodium bicarbonate
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
US6927296B2 (en) 2003-07-23 2005-08-09 Pfizer Inc. Process
GB0317229D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Improved process
US7241805B2 (en) 2005-06-27 2007-07-10 Biovail Laboratories, Inc. Modified release formulations of a bupropion salt
RU2313340C1 (ru) * 2006-02-20 2007-12-27 Дмитрий Владимирович Зимин Лекарственное средство, обладающее противомигренозным действием, и способ его изготовления
ATE502921T1 (de) * 2006-10-19 2011-04-15 Auspex Pharmaceuticals Inc Substituierte indole
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
EP1956018A1 (de) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung eines Benzimidazolderivats
US20080287519A1 (en) * 2007-05-01 2008-11-20 Marioara Mendelovici Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
EP2038273A1 (en) * 2007-05-29 2009-03-25 Plus Chemicals B.V. A process for preparing 5-bromo-3-[(r)-1-methyl-pyrrolidin-2-ylmethyl]-1h-indole
EP2225224A2 (en) * 2007-12-17 2010-09-08 Actavis Group PTC EHF Novel hemioxalate salt of eletriptan
WO2009142771A2 (en) * 2008-05-22 2009-11-26 Plus Chemicals, S.A. Salts of (r)-5-(2-phenylsulphonylethenyl)-3-(n- methylpyrrolidin-2-ylmethyl)-1h-indole, 5-bromo-3-[(r)-1- methyl-pyrrolidin-2- ylmethyl]-1h-indole and of eletriptan
CA2731041C (en) 2008-08-07 2016-09-06 Biovail Laboratories International Srl Bupropion hydrobromide polymorphs
US20120027816A1 (en) * 2009-02-25 2012-02-02 Actavis Group Ptc Ehf Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
IT1393700B1 (it) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
WO2011004391A2 (en) 2009-06-25 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of eletriptan and its salt thereof
US8754239B2 (en) 2010-01-19 2014-06-17 Sms Pharmaceuticals Limited Process for preparing eletriptan hydrobromide having α-form
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
JP2019502761A (ja) 2016-01-21 2019-01-31 ラボラトリオス レヴィ エセエレ （（ｒ）−３−［（−１−メチルピロリジン−２−イル）メチル］−５−（２−フェニルスルホニルエチル）−１ｈ−インドールを作製する方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2773875A (en) * 1952-03-28 1956-12-11 Hoffmann La Roche Indole derivatives and method for producing same
GB886684A (en) * 1957-09-17 1962-01-10 Upjohn Co Improvements in or relating to heterocyclic compounds and the manufacture thereof
GB851780A (en) * 1958-02-25 1960-10-19 Rhone Poulenc Sa New indole derivatives
US3037031A (en) * 1959-08-04 1962-05-29 Warner Lambert Pharmaceutical Derivatives of 3-(2-aminoalkyl)-5-indolol and process therefor
GB893707A (en) * 1960-03-01 1962-04-11 Roche Products Ltd Novel tryptamine derivatives and a process for the manufacture thereof
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
ES2104733T3 (es) * 1990-10-15 1997-10-16 Pfizer Derivados de indol.
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5208248A (en) * 1991-01-11 1993-05-04 Merck Sharpe & Dohme, Ltd. Indazole-substituted five-membered heteroaromatic compounds
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
ATE190608T1 (de) * 1991-11-25 2000-04-15 Pfizer 5-(hetero- oder carbocyclylamino)-indol derivate, deren herstellung und deren verwendung als 5-ht1 agonisten
GB9201038D0 (en) * 1992-01-16 1992-03-11 Glaxo Group Ltd Chemical compounds
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
TW288010B (es) * 1992-03-05 1996-10-11 Pfizer
UA27467C2 (uk) * 1992-04-07 2000-09-15 Пфайзер Інк. ПОХІДНІ ІНДОЛУ ЯК 5-НТ<sub>1</sub> АГОНІСТИ ТА ПРОМІЖНІ СПОЛУКИ
CZ282653B6 (cs) * 1992-04-10 1997-08-13 Pfizer Inc. Acylaminoindolové deriváty představující 5-HT1 agonisty, způsob jejich přípravy, farmaceutické prostředky obsahující tyto látky, jejich použití a meziprodukty postupu přípravy
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
EP0695301B1 (en) * 1993-04-22 1996-10-30 Pfizer Limited Indole derivatives as 5-ht1-like agonists for use in migraine
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
DK0716649T3 (da) * 1993-08-31 1999-02-08 Pfizer 5-Arylindolderivater

Also Published As

Publication number Publication date
KR100228952B1 (ko) 1999-11-01
NO311297B1 (no) 2001-11-12
HU227822B1 (en) 2012-03-28
SA95160156B1 (ar) 2005-05-30
DE69501620T2 (de) 1998-07-02
DK0776323T3 (da) 1998-03-30
ES2112650T3 (es) 1998-04-01
PL180867B1 (pl) 2001-04-30
LV11800B (en) 1997-10-20
SI9520091B (sl) 2004-10-31
AP576A (en) 1997-03-20
HRP950460B1 (en) 2000-02-29
IL115013A (en) 2000-11-21
AU691005B2 (en) 1998-05-07
IS4401A (is) 1996-12-19
CZ287693B6 (en) 2001-01-17
YU56995A (sh) 1998-07-10
CA2198599C (en) 2000-06-06
SK282922B6 (sk) 2003-01-09
CA2198599A1 (en) 1996-03-07
US6110940A (en) 2000-08-29
NO970861D0 (no) 1997-02-26
JPH09512283A (ja) 1997-12-09
RU2159241C2 (ru) 2000-11-20
NO970861L (no) 1997-02-26
NZ288210A (en) 1998-01-26
RO116400B1 (ro) 2001-01-30
US6380226B1 (en) 2002-04-30
PL318319A1 (en) 1997-06-09
EP0776323B1 (en) 1998-02-11
FI970800A0 (fi) 1997-02-26
CZ56397A3 (cs) 1998-05-13
SK24897A3 (en) 1998-08-05
IL115013A0 (en) 1995-12-08
FI970800L (fi) 1997-02-26
ZA957142B (en) 1997-02-25
SI9520091A (sl) 1998-02-28
DZ1923A1 (fr) 2002-02-17
YU49287B (sh) 2005-03-15
FI113768B (fi) 2004-06-15
TNSN95092A1 (fr) 1996-02-06
BR9503812A (pt) 1996-04-16
BG101250A (en) 1997-09-30
EP0776323A1 (en) 1997-06-04
LV11800A (lv) 1997-06-20
AU2735295A (en) 1996-03-22
JP2904588B2 (ja) 1999-06-14
MY113733A (en) 2002-05-31
MA23650A1 (fr) 1996-04-01
OA10600A (en) 2000-04-06
HUT77310A (hu) 1998-03-30
KR970705557A (ko) 1997-10-09
PE41596A1 (es) 1996-10-12
HRP950460A2 (en) 1997-08-31
CN1066727C (zh) 2001-06-06
TR199501061A2 (tr) 1996-06-21
BG61840B1 (bg) 1998-07-31
IS1850B (is) 2003-02-07
GR3026475T3 (en) 1998-06-30
CN1155886A (zh) 1997-07-30
WO1996006842A1 (en) 1996-03-07
DE69501620D1 (de) 1998-03-19
CO4410334A1 (es) 1997-01-09
AP9500754A0 (en) 1995-07-31
BRPI9503812B1 (pt) 2017-04-18
UA45980C2 (uk) 2002-05-15
GB9417310D0 (en) 1994-10-19
EG23822A (en) 2007-09-19
ATE163182T1 (de) 1998-02-15

Similar Documents

Publication Publication Date Title
MX9701538A (es) Sales de un derivado del indol contra la migraña.
IL133623A0 (en) Antithrombotic agents
IL133627A0 (en) Antithrombotic agents
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
AU4264396A (en) Cosmetic or pharmaceutical compositions containing mangiferin or derivatives thereof
IL112622A0 (en) Camptothecin derivatives, their preparation and pharmaceutical compositions containing them
PL320560A1 (en) Pharmaceutic composition
UA35607C2 (uk) Похідні оксазолідинонкарбонової кислоти, спосіб їх одержання, фармацевтична композиція і спосіб її одержання
NZ216048A (en) Quinolylglycinamide derivatives, and pharmaceutical compositions containing such
ES8601915A1 (es) Un procedimiento para preparar derivados de piridazinona
AP9300561A0 (en) Antibiotic compounds.
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
MY137475A (en) Chemical compounds.
GR1002576B (el) Φαρμακευτικες συνθεσεις και μια μεθοδος παρασκευης τους.
EP1027051A4 (en) ANTITHROMBOTIC AGENTS
MY118946A (en) Novel intermediates and their use to prepare n, n&#39;&#39;- bridged bisindolylmaleimides
TW339325B (en) Novel azepane derivatives, process for the preparation thereof and pharmaceutical composition containing the same
MY106235A (en) New 2 - carbonyl substituted n, n&#39;&#39; -di (trimethoxybenzoyl) piperazines, process for preparing the same and therapeutical compounds containing them.
DE3663947D1 (en) New indole derivatives, the production and uses thereof
TW344650B (en) Fungicidal compositions and the process for the preparation thereof
MY109729A (en) Benzofuranylimidazole derivatives, a process for the preparation and therapeutical compositions containing the same
IL114646A0 (en) Method of inhibiting leukotriene biosynthesis
AP9400608A0 (en) &#34;New nicotinic acid derivative&#34;.
AU1466592A (en) Gem-diphosphonic acid nitrosocarbamoyl derivatives, a process for the preparation thereof and pharmaceutical compositions containing them
ES2027507A6 (es) Procedimiento de preparacion de derivados selenofenicos.

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: PFIZER IRELAND PHARMACEUTICALS